Ming Kyler Lei - 18 Mar 2026 Form 3 Insider Report for NovaBridge Biosciences (NBP)

Role
Chief Financial Officer
Signature
/s/ Xi-Yong (Sean) Fu as attorney-in-fact
Issuer symbol
NBP
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 21:40:09 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lei Ming Kyler Chief Financial Officer C/O NOVABRIDGE BIOSCIENCES,, 2440 RESEARCH BOULEVARD, SUITE 400, ROCKVILLE /s/ Xi-Yong (Sean) Fu as attorney-in-fact 18 Mar 2026 0002108366

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NBP 2025 Employee Share Option (right to buy) 18 Mar 2026 Ordinary Shares 996,775 $4.25 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
F2 Number of underlying securities and exercise price expressed in terms of ADSs.
F3 The option was granted on October 16, 2025. The option vests and becomes exercisable over five years, with four-tenths vesting on the second anniversary of the grant date and the balance vesting ratably on each subsequent anniversary of the grant date.

Remarks:

Exhibit List: Ex. 24.1 - Power of Attorney